“… [ 49 ] | HFD-fed, Fat-1 transgenic mice | NLRP3 | Increased HFD-induced expression of NLRP3, production of IL-1β and IL-18, and increased activity of caspase-1 in adipose tissue | [ 50 ] |
HFD-fed, or STZ-induced diabetic Sprague–Dawley rats | NLRP3 | Increased expression of NLRP3 inflammasome components (NLRP3, ASC, caspase-1, IL-1β), NF-kB, and Nrf2 in liver | [ 51 ] |
T1D | Blood mononuclear cells (PBMCs) from T1DM patients | NLRP1, NLRP3 | Lower NLRP1, NLRP3, caspase-1 and IL-1β expressions. | [ 52 ] |
STZ-induced T1DM rat | NLRP3 | Increased NLRP3, IL-18, IL1β and GSDM-D protein levels in nucleus pulposus tissues | [ 53 ] |
NAFLD | Liver and primary hepatocyte from HFD-fed mice | NLRP3 | Increased expressions of NLRP3, ASC, caspase-1, and increased caspase-1 activity and IL-1β level | [ 54 ] |
Visceral adipose tissue from NAFLD/NASH patients | NLRP4, NLRP6 | Downregulated NLRP4, IL-1β, and upregulated NLRP6 expression in visceral adipose tissue, and increased circulating IL-18 levels in patients with pericellular fibrosis. | [ 55 ] |
Liver samples from NAFLD patients, and ob/ob or Nlrp2 −/− mice | NLRP2 | Decreased mRNA and protein expression of Nlrp2 in NAFLD patient, and Nlrp2 −/− enhanced HFD-induced metabolic syndrome and insulin resistance. |
…”